Pseudoephedrine: Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Navigation

DRUG NAME: Pseudoephedrine

Therapeutic Class: Sympathomimetic (Nasal Decongestant)
Subclass: Alpha-adrenergic agonist
Speciality: Otorhinolaryngology

Schedule (India): Schedule H
Route(s): Oral
Formulations Available in India:
• Tablets: 30 mg, 60 mg
• Syrup: 30 mg/5 mL
• Fixed-dose combinations (FDC) with antihistamines (e.g., chlorpheniramine, cetirizine, loratadine) and/or analgesics commonly available

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Nasal Congestion (due to allergic rhinitis, upper respiratory tract infection, sinusitis)

Adults:

Parameter	Recommendation
Starting dose	30–60 mg orally every 4–6 hours as required
Titration	Not applicable; dose adjusted based on symptom relief
Usual maintenance dose	60 mg every 6 hours
Maximum dose	240 mg/day
Duration	Short-term use only (≤5–7 days recommended)

Clinical Notes:
• May be used as monotherapy or as part of FDC with antihistamines/analgesics
• Efficacy reduced in severe inflammation or chronic rhinitis
• Avoid use near bedtime due to stimulant effects
• Oral pseudoephedrine does not cause rebound congestion (unlike topical nasal decongestants)

Secondary Indications — Adults (Off-label, if any)

▶ Stress Urinary Incontinence — OFF-LABEL

Parameter	Recommendation
Starting dose	60 mg orally three times daily
Titration	Not applicable
Usual maintenance dose	60 mg three times daily
Maximum dose	180 mg/day
Duration	As assessed by urogynecology specialist

• Specialist only
• Evidence basis: Small RCTs and anecdotal clinical use; mechanism via alpha-adrenergic stimulation of bladder neck smooth muscle

PAEDIATRIC DOSING (Specialist Only)

Primary Indication

▶ Nasal Congestion (Short-term symptomatic relief)

Age Group	Starting Dose	Frequency	Maximum Daily Dose	Maximum Duration
6–12 years	30 mg orally	Every 6 hours	120 mg/day	≤5–7 days
2–5 years	15 mg orally	Every 6 hours	60 mg/day	≤5 days

Clinical Notes:
• When using FDC syrups, calculate dose based on pseudoephedrine content
• Not recommended in children <2 years unless specifically advised by paediatric specialist

Safety Monitoring:
• Monitor for irritability, insomnia, palpitations
• Avoid bedtime dosing
• Discontinue if tachycardia or behavioural changes noted

Secondary Indications — Paediatric Doses (Off-label, if any)

Not applicable — No established paediatric off-label indications in Indian practice.

RENAL ADJUSTMENT

Renal Function	Recommendation
eGFR ≥30 mL/min/1.73m²	No dose adjustment required
eGFR <30 mL/min/1.73m²	Use with caution; extend dosing interval to every 8–12 hours
Haemodialysis	Limited data available; potential for accumulation — avoid unless necessary

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required; monitor for adverse effects
Moderate impairment	No dose adjustment required; monitor for CNS side effects
Severe impairment	Use with caution; CNS adverse effects may be increased

CONTRAINDICATIONS

• Severe hypertension
• Severe coronary artery disease
• Narrow-angle glaucoma
• Concurrent or recent (within 14 days) use of monoamine oxidase inhibitors (MAOIs)
• Known hypersensitivity to pseudoephedrine or any formulation excipient

CAUTIONS

• Mild to moderate hypertension
• Diabetes mellitus (may elevate blood glucose levels)
• Hyperthyroidism
• Prostatic hypertrophy (may worsen urinary retention)
• Anxiety disorders
• Seizure disorders or concurrent use of seizure threshold-lowering medications
• Elderly patients (heightened sensitivity to stimulatory effects)
• Paediatric population (increased sensitivity to CNS stimulation)
• Ischaemic heart disease

PREGNANCY

Consideration	Recommendation
Overall safety	Use with caution; limited safety data in Indian obstetric sources
Risk	Avoid during first trimester — possible association with abdominal wall defects (gastroschisis) based on limited international data
When it may be used	Only if benefits clearly outweigh risks; avoid prolonged use
Preferred alternatives	Antihistamines like chlorpheniramine (in second trimester onwards) if symptomatic relief required
Monitoring	Maternal blood pressure; fetal growth if repeated use necessary

LACTATION

Consideration	Recommendation
Compatibility	Compatible with breastfeeding in short-term, occasional use
Drug levels in milk	Low
Preferred alternatives	Short-acting antihistamines (e.g., loratadine) if available
Infant monitoring	Irritability, sleep disturbances, poor feeding

ELDERLY

Consideration	Recommendation
Starting dose	30 mg every 6–8 hours (lower end of dose range)
Titration	Slower titration preferred
Risks	Confusion, insomnia, urinary retention, blood pressure elevation, tachycardia
Monitoring	Blood pressure, heart rate, urinary symptoms, CNS effects

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Monoamine oxidase inhibitors (MAOIs)	Risk of hypertensive crisis due to potentiation of sympathomimetic effects	Contraindicated — avoid within 14 days of MAOI use
Linezolid	MAOI activity; risk of serotonin syndrome and hypertensive crisis	Avoid combination
Tricyclic antidepressants (e.g., amitriptyline)	Potentiation of vasopressor effect	Avoid or monitor closely
Digoxin	Potential to aggravate arrhythmias	Use with caution; monitor cardiac rhythm

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect / Mechanism	Recommendation
Beta-blockers	May reduce antihypertensive efficacy, especially non-selective agents	Monitor blood pressure
Antihypertensives (esp. alpha-blockers)	Risk of blood pressure elevation	Monitor blood pressure closely
SSRIs/Serotonergic drugs	Rarely associated with additive CNS stimulation	Monitor for toxicity
Caffeine	Additive stimulation effects	Advise limiting caffeine intake
Sympathomimetics (other decongestants)	Additive cardiovascular effects	Avoid concurrent use

COMMON ADVERSE EFFECTS

• Insomnia
• Nervousness, restlessness
• Palpitations
• Tachycardia
• Dry mouth
• Headache
• Dizziness
• Anorexia

SERIOUS ADVERSE EFFECTS

Adverse Effect	Clinical Note
Hypertensive crisis	Especially with MAOIs or overdose; requires immediate discontinuation and emergency management
Arrhythmias	Rare; more likely in patients with pre-existing heart disease
Seizures	Rare; especially in overdose or young children
Psychosis-like symptoms	May occur with high doses or prolonged use
Acute urinary retention	Especially in older males with prostatic hypertrophy

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Blood pressure, heart rate in patients with cardiovascular risk factors
After initiation	Monitor for insomnia, palpitations, blood pressure changes
Long-term	Not recommended for chronic use (>7 days); reassess need and consider alternative management

BRANDS AVAILABLE IN INDIA

Single-ingredient formulations:
• Sudafed (limited availability)

Common FDC brands (with antihistamines/analgesics):
• Solvin Cold
• Sinarest
• Alerid-D (with cetirizine)
• Lorfast-D (with loratadine)
• Zeet P
• Snicold
• Cheston Cold

Note: Most market availability is in FDC form rather than single-ingredient preparations

PRICE RANGE (INR)

• Tablets (60 mg): ₹1.50–₹4.00 per tablet
• Syrups (FDCs): ₹20–₹60 per 60 mL bottle
• Prices vary significantly with combinations and brands
• Not under NPPA price control

CLINICAL PEARLS

• Choose plain pseudoephedrine for isolated congestion; use antihistamine combinations when sneezing, rhinorrhoea, or itching are also present
• Avoid administration near bedtime — stimulant effects commonly cause insomnia
• Oral pseudoephedrine is safer than topical nasal decongestants (oxymetazoline, xylometazoline) as it does not cause rebound congestion (rhinitis medicamentosa)
• Not advisable in children <2 years unless strictly necessary under specialist guidance
• Restrict duration to ≤5–7 days to minimise tolerance development and stimulant adverse effects
• Always verify absence of concurrent MAOI use before prescribing

VERSION

RxIndia v1.0 — 19 Feb 2026

REFERENCES

• CDSCO
• Indian Pharmacopoeia (IP)
• National Formulary of India (NFI)
• NLEM 2022
• API Textbook of Medicine
• IAP Guidelines for Respiratory Infections
• AIIMS Drug Formulary
• Select RCT data (for off-label urinary incontinence indication)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.